• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY:LLY)

    1,231.94 +46.23 (+3.90%)
    Official Closing Price Updated: 7:00 PM EDT, Aug 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Eli Lilly

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Why Eli Lilly Topped the Market Today ↗
    One of its more popular products just got the green light from a major national regulator. 
    Via The Motley Fool
    News headline image
    Eli Lilly Upgraded, Best Buy Downgraded: Updated Rankings on Top Blue-Chip Stocks ↗
    During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. 
    Via InvestorPlace
    Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup ↗
    Via Chartmill
    News headline image
    Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗
    It's not much of a rivalry yet. 
    Via The Motley Fool
    News headline image
    iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗
    XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Eli Lilly and Company Q2 Earnings Call Highlights ↗
    Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗
    XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns. 
    Via The Motley Fool
    Topics ETFs Economy
    News headline image
    Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗
    Can anyone take the top spot away from Eli Lilly in the anti-obesity area? 
    Via The Motley Fool
    News headline image
    Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
    Berobenatide is one of the keys to Pfizer's future. 
    Via The Motley Fool
    News headline image
    Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’ ↗
    Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B. 
    Via Benzinga
    News headline image
    Every S&P 500 Sector ETF Ranked by How Much It Actually Depends on Just 3 Stocks ↗
    Sector ETFs give the impression of diversification. Most of them don't have it. 
    Via The Motley Fool
    Topics Artificial Intelligence ETFs Stocks
    News headline image
    Prediction: This Unstoppable Vanguard ETF Will Crush the S&P 500 in the Remainder of 2026 ↗
    Some of America's largest growth stocks had a sluggish start to 2026, but they're bouncing back. 
    Via The Motley Fool
    Topics Artificial Intelligence ETFs Stocks
    News headline image
    Why Is Everyone Talking About Novo Nordisk? ↗
    The drugmaker continues to face headwinds. 
    Via The Motley Fool
    News headline image
    CVS Health Q2 Earnings Call Highlights ↗
    CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Global Abemaciclib Market to Reach USD 3.18 Billion by 2034, Growing at 9.7% CAGR ↗
    Global Abemaciclib Market to Reach USD 3.18 Billion by 2034, Growing at 9.7% CAGR According to the latest market intelligence from Intel Market Research, t 
    Via Talk Markets
    Topics Intellectual Property
    SpaceX First-Quarter Print And A DeepMind Exit Split The Tape As Records Take A Breather ↗
    Via Chartmill
    News headline image
    LLY Q2 Deep Dive: Key Products and Pipeline Expansion Offset Revenue Miss
    Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to ... 
    Via StockStory
    News headline image
    Why Eli Lilly Stock Climbed Today ↗
    Demand for the healthcare leader's weight-loss drugs continues to rise. 
    Via The Motley Fool
    News headline image
    State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗
    XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning Markets ↗
    On Aug. 5, 2026, new highs across major indexes reflect renewed confidence in global trade as investor confidence starts to return. 
    Via The Motley Fool
    Topics Artificial Intelligence Earnings Stocks
    Top S&P500 movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion ↗
    Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more. 
    Via Benzinga
    News headline image
    Eli Lilly (LLY) Stock Trades Up, Here Is Why
    What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.5% in the morning session after the company delivered a massive "beat an... 
    Via StockStory
    News headline image
    Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings ↗
    Stocks mixed as Nasdaq falls 100 points, Dow rises .79%. Eli Lilly beats earnings estimates, Digital Turbine surges 43%, oil down .4%, gold up 2.5% 
    Via Benzinga
    Topics Stocks
    News headline image
    The FTC Is Suing Hims & Hers Health—Here's Why Investors Shouldn't Panic ↗
    Hims & Hers Health shares have rallied despite an FTC lawsuit over data sharing and billing practices, as weight-loss drug partnerships and Wall Street's cautious Hold rating shape the stock's outlook... 
    Via MarketBeat
    Topics Lawsuit
    News headline image
    CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal ↗
    CVS Health beats Q2 earnings expectations and hikes FY26 guidance, but shares fall on profit-taking. Get the full financial breakdown. 
    Via Benzinga
    Which S&P500 stocks are gapping on Wednesday? ↗
    Via Chartmill
    News headline image
    Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop ↗
    Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity. 
    Via Investor's Business Daily
    Wondering what's happening in today's S&P500 pre-market session? ↗
    Via Chartmill
    News headline image
    Eli Lilly (NYSE:LLY) Beats Expectations in Strong Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations
    Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 47.7% year on year t... 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.